Literature DB >> 2442162

RNase H activity associated with bacterially expressed reverse transcriptase of human T-cell lymphotropic virus III/lymphadenopathy-associated virus.

J Hansen, T Schulze, K Moelling.   

Abstract

The reverse transcriptase polymerase of the human T-cell lymphotropic virus/lymphadenopathy-associated virus has been cloned into an expression vector and expressed in Escherichia coli. Two polypeptides of 66 and 51 kDa molecular mass are detectable in polymerase-expressing bacterial lysates with human patient sera. They are processed from a short-lived 120-kDa polyprotein precursor equivalent to a region consisting of polymerase, protease, and endonuclease. The 51 kDa protein appears to originate from the 66-kDa molecule; additional processing products are 32- and 15-kDa proteins. The bacterially expressed polymerase is enzymatically active and exhibits the template specificities, ion requirements, and response to inhibitors of the authentic enzyme. It was purified by DEAE-cellulose-, phosphocellulose-, and poly(rC)-agarose column chromatography followed by glycerol density gradient centrifugation. It copurifies with an RNase H activity, suggesting the existence of a virus-coded DNA polymerase-RNase H complex. The purified bacterial enzyme allows a safe large-scale screening for inhibitors of both activities.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2442162

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Regulation of the reverse transcriptase of human immunodeficiency virus type 1 by dNTPs.

Authors:  A B West; T M Roberts; R D Kolodner
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

2.  Mutational analysis of human immunodeficiency virus type 1 protease suggests functional homology with aspartic proteinases.

Authors:  D D Loeb; C A Hutchison; M H Edgell; W G Farmerie; R Swanstrom
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

3.  Tighter binding of HIV reverse transcriptase to RNA-DNA versus DNA-DNA results mostly from interactions in the polymerase domain and requires just a small stretch of RNA-DNA.

Authors:  William P Bohlayer; Jeffrey J DeStefano
Journal:  Biochemistry       Date:  2006-06-20       Impact factor: 3.162

4.  Substrate inhibition of the human immunodeficiency virus type 1 reverse transcriptase.

Authors:  P A Furman; G Painter; J E Wilson; N Cheng; S Hopkins
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

5.  Quantitative analysis of RNA cleavage during RNA-directed DNA synthesis by human immunodeficiency and avian myeloblastosis virus reverse transcriptases.

Authors:  J J DeStefano; L M Mallaber; P J Fay; R A Bambara
Journal:  Nucleic Acids Res       Date:  1994-09-11       Impact factor: 16.971

6.  G-->A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription.

Authors:  J P Vartanian; A Meyerhans; M Sala; S Wain-Hobson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

7.  Human immunodeficiency virus nucleocapsid protein stimulates strand transfer from internal regions of heteropolymeric RNA templates.

Authors:  J J DeStefano
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

8.  Determinants of the RNase H cleavage specificity of human immunodeficiency virus reverse transcriptase.

Authors:  J J DeStefano; L M Mallaber; P J Fay; R A Bambara
Journal:  Nucleic Acids Res       Date:  1993-09-11       Impact factor: 16.971

9.  Mechanism analysis indicates that recombination events in HIV-1 initiate and complete over short distances, explaining why recombination frequencies are similar in different sections of the genome.

Authors:  Sean T Rigby; April E Rose; Mark N Hanson; Robert A Bambara
Journal:  J Mol Biol       Date:  2009-02-20       Impact factor: 5.469

10.  Two highly antigenic sites in the human immunodeficiency virus type 1 reverse transcriptase.

Authors:  E Björling; C A Boucher; A Samuelsson; T F Wolfs; G Utter; E Norrby; F Chiodi
Journal:  J Clin Microbiol       Date:  1993-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.